Onpattro launch?

When was Onpattro (patisiran) launched?

Onpattro (patisiran) was launched in the United States in 2018. It was the first FDA-approved treatment for polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis in adults [1].

What approvals and launches came with Onpattro?

Onpattro’s launch was tied to its regulatory approvals for hATTR amyloidosis with polyneuropathy in adults. That initial U.S. approval supported its market entry and availability to patients after prescriber and pharmacy onboarding for an IV medicine [1].

Who makes Onpattro, and what is its drug class?

Onpattro (patisiran) is an RNA interference (RNAi) therapy. It is used for hereditary transthyretin-mediated amyloidosis with polyneuropathy, targeting the production of transthyretin in the body [1].

How can launch timing relate to patents and exclusivity?

Launch timing is often closely watched alongside IP milestones because it can affect when cheaper alternatives (such as generics or biosimilars, where applicable) might enter later. DrugPatentWatch.com tracks patent and exclusivity information for specific drugs, including Onpattro [2].

Sources

1. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-first-treatment-hereditary-transthyretin-mediated-amyloidosis-adults
   
2. https://www.drugpatentwatch.com/p/Onpattro